Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Arts
  • Entertainment
  • Non-profit
  • Technology
  • Books
ncarol.com

OncoBeta introduces Rhenium-SCT for non-melanoma skin cancer patients at Hospital Universitario 12 de Octubre
ncarol.com/10264760

Trending...
  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart
  • Streamlining Seasonal Shutdowns: SPX FLOW Ensures Operational Continuity
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
OncoBeta team stand with the treating physicians Patient undergoing treatment with Rhenium-SCT
MADRID - ncarol.com -- OncoBeta®, a leading medical device company specialising in innovative epidermal radioisotope therapies, today announced Hospital Universitario 12 de Octubre, in Madrid, has treated its first patient with Rhenium-SCT® (skin cancer therapy) – and is expected to continue offering this therapy for patients with non-melanoma skin cancers (NMSCs).

Rhenium skin cancer therapy is an advanced radionuclide therapy technology that offers a painless,*1,2 single-session,†1-3 non-invasive‡1 treatment without disfiguring scarring.1,4 Treatment with Rhenium-SCT employs a superficial application of a paste containing β-emitting particles directly to the NMSC lesion, targeting cancer cells without the need for surgery.1,4

Shannon D. Brown III, CCO at OncoBeta, says, "With rates of NMSC increasing globally, we feel it's vitally important that new treatment options are offered to patients. Surgical intervention continues to be the most common treatment, but it can lead to disappointing results. Rhenium skin cancer therapy addresses many patients' desires for a non-surgical alternative – with simple application directly to the lesion, treatment time generally ranges 45 to 180 mins, which means patients can continue with their lives with very little disruption."

New cases of NMSCs in Spain are expected to almost double from 2022-2050 according to latest figures by the International Agency of Research on Cancer as part of the World Health Organization,5 making Mardrid an important location for this innovative NMSC treatment option.

"Rhenium-SCT has long been accessible to patients across Europe. This new clinic in Spain marks a significant milestone in expanding access to this innovative treatment for non-melanoma skin cancer patients," Mr Brown explains.

Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. It offers a patient-friendly treatment alternative and we are delighted to have another medical facility offering Rhenium-SCT to those suffering with NMSCs".

More on ncarol.com
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock

___

About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.1 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1,4

The Rhenium-SCT is a painless,*1,2  single session,†1-3 non-invasive‡1 therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.1,4,6 The Rhenium-SCT utilizes the radioisotope rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalized therapy that is only applied to the area needed to treat without affecting the healthy tissue.4,6 The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (basal cell carcinomas and squamous cell carcinomas) can be treated using the Rhenium-SCT in one single session. †1-4 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.1,6,7

About OncoBeta®
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT at www.oncobeta.com

More on ncarol.com
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

*No reported pain during procedure.1,2
†
Complete tumour regression in 98.5% of lesions treated.3
‡
A treatment is considered non-invasive when no cut or break in the skin is created.8

References
  1. Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021; 48: 1511–1521.
  2. Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
  3. Cipriani C, et al. In Therapeutic Nuclear Medicine. 2014. RP Baum (Ed), New York: Springer.
  4. Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
  5. Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
  6. Cipriani C, et al. International J Nucl Med. 2017; July:114–112.
  7. Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745–749.
  8. Australian Therapeutic Goods Administration. Acronym and glossary of terms. Available at: https://www.tga.gov.au/resources/acronyms-and-glossary-terms. (Accessed June 2024).


Contact
Jane Morey
***@moreymedia.com.au


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Suzanne Harp named Managing Director in Texas, USA
  • $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
  • Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
  • This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
  • An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart
  • Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
  • Streamlining Seasonal Shutdowns: SPX FLOW Ensures Operational Continuity
  • IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
  • Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion
  • Mortgage Rates And Demand Are Stuck In A Holding Pattern
  • Coker Completes Acquisition of Healthcare Cost Solutions, a Leading Expert in Technology-Enabled Compliance Services
  • Industry's First-Ever LTL Freight Claims Index
  • Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
  • K2 Integrity's U.S. and EMEA Teams Recognized in Chambers and Partners 2025 Guides
_catLbl0 _catLbl1

Popular on ncarol.com

  • RNHA Named Official Community Partner of the First Annual CPAC Latino 2025 - 115
  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
  • $750 Million Market Projected to Reach $3.3 Billion Globally in 2034 for New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharma, Inc
  • JU Miner Launches Free Mining: Bitcoin, Dogecoin, and Litecoin
  • Pregis Empowers Foam-in-Place Customers to Fight Water Insecurity with Inspyre Film
  • Scott Burton Announces Chaos: Volume 1 – A Journal of Being Human
  • June 2-8 is Medicare Fraud Prevention Week
  • Fusion Marketing Group Celebrates 15 Years of Transforming Healthcare Recruitment Marketing
  • Shelter Structures America Appoints Shannon Heller as New Inventory Manager, Bolstering Operational Excellence in the Commercial Tent Industry

Similar on ncarol.com

  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
  • Gastonia Pediatric Associates Welcomes Charlene Guffey, FNP-C, to Expanding Medical Team
  • Dr. Nima Missaghian to join Carolina Surgical Arts in Greensboro, NC
  • Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
  • Coker Completes Acquisition of Healthcare Cost Solutions, a Leading Expert in Technology-Enabled Compliance Services
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute